Alpha-1-proteinase inhibitor human
Package labels
Loading package label images…
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Specialty pharmacy: therapy management checklist, storage and cold chain, dosing calendar, Medicare Part D coverage.
Dosing in kidney impairment
This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.
Preparation and administration
Prepare this dose
Your numbers for alpha-1-proteinase inhibitor human. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
When reconstituted as directed, Zemaira ® may be administered intravenously at a rate of approximately 0.08 mL/kg/min as determined by the response and comfort of the patient. The recommended dosage of 60 mg/kg body weight will take approximately 15 minutes to infuse. Preparation Each product package contains one Zemaira ® single use vial, one 20 mL vial of Sterile Water for Injection, USP (diluent) and one color-coded vented transfer device with air inlet filter.
Administer within three hours after reconstitution. Reconstitution 1. Bring both product (green cap) vial and diluent (white cap) vial to room temperature prior to reconstitution. 2. Remove the plastic flip-top caps from the vials. Aseptically cleanse the rubber stoppers with antiseptic solution and allow them to dry. [See table below.] 3.
Allow the vacuum in the Zemaira ® vial to pull the diluent into the Zemaira ® vial. 6. During diluent transfer, wet the lyophilized cake completely by gently tilting the Zemaira ® vial. (Fig. 4) Do not allow the air inlet filter to face downward. Care should be taken not to lose the vacuum, as this will prolong reconstitution of the product. 7.
Gently swirl the Zemaira ® vial until the powder is completely dissolved. (Fig. 5) DO NOT SHAKE . 9. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. Administer at room temperature within three hours after reconstitution. Fig. 2 Fig. 3 Fig. 4 Fig. 5 Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Pooling Reconstituted Vials If more than one vial of Zemaira ® is needed to achieve the required dose, use an aseptic technique to transfer the reconstituted solution from the vials into the administration container (e.g., empty I.V. bag or glass bottle).
Administration Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration. Administer at room temperature within three hours after reconstitution. Filter the reconstituted solution during administration. To ensure proper filtration of Zemaira ® , use an I.V. administration set with a suitable 5 micron infusion filter (not supplied).
Follow the appropriate procedure for I.V. administration. After administration, any unused solution and administration equipment should be discarded in accordance with biohazard procedures.
| NOTE: | The transfer device (Fig. 1) provided in the package is comprised of a white (diluent) end, which has a double orifice, and a green (product) end, which has a single orifice. Incorrect use of the transfer device will result in loss of vacuum and prevent transfer of the diluent, thereby preventing reconstitution of the product. |
| Fig. 1 | |
| The transfer device is sterile. Do not touch the exposed ends of the spike after removing the protective covers. |
Drug interactions
Check interactions
Add the patient's other drugs. Matches come from both FDA labels: by name, drug class, and enzyme or transporter pathway.
- Alpha-1-proteinase inhibitor human
Contraindications
Zemaira ® is contraindicated in individuals with a known hypersensitivity to any of its components. Zemaira ® is also contraindicated in individuals with a history of anaphylaxis or severe systemic response to A 1 -PI products. Zemaira ® is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for alpha-1-proteinase inhibitor human. Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
Pregnancy Category C Animal reproduction studies have not been conducted with Zemaira ® . It is also not known whether Zemaira ® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Zemaira ® should be given to a pregnant woman only if clearly needed.
Lactation
Nursing Mothers It is not known whether Zemaira ® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Zemaira ® is administered to a nursing woman.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.